Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.

MLA

Tanaka, Mamoru, et al. “Combination of Talaporfin Photodynamic Therapy and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Gastric Cancer.” Biochemical & Biophysical Research Communications, vol. 539, Feb. 2021, pp. 1–7. EBSCOhost, https://doi.org/10.1016/j.bbrc.2020.12.073.

APA

Tanaka, M., Sasaki, M., Suzuki, T., Nishie, H., & Kataoka, H. (2021). Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer. Biochemical & Biophysical Research Communications, 539, 1–7. https://doi.org/10.1016/j.bbrc.2020.12.073

Chicago

Tanaka, Mamoru, Makiko Sasaki, Taketo Suzuki, Hirotada Nishie, and Hiromi Kataoka. 2021. “Combination of Talaporfin Photodynamic Therapy and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Gastric Cancer.” Biochemical & Biophysical Research Communications 539 (February): 1–7. doi:10.1016/j.bbrc.2020.12.073.